Neurocrine Biosciences
NBIX
NBIX
274 hedge funds and large institutions have $9.03B invested in Neurocrine Biosciences in 2018 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 98 increasing their positions, 96 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
2% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 96
0.94% less ownership
Funds ownership: 103.16% → 102.23% (-0.94%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Holders
274
Holding in Top 10
6
Calls
$73.1M
Puts
$69.3M
Top Buyers
| 1 | +$80.6M | |
| 2 | +$37M | |
| 3 | +$32M | |
| 4 |
Two Sigma Advisers
New York
|
+$27.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.3M |
Top Sellers
| 1 | -$52.2M | |
| 2 | -$33.6M | |
| 3 | -$33.2M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32.8M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$31.3M |